Octopharma has initiated a Phase II/III Study of its intravenous immunoglobulin preparation (IVIG) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
The study will be randomised, double-blind, placebo-controlled, adaptive and multi-centre, and will evaluate the safety and efficacy of Octapharma’s 10% novel intravenous immunoglobulin for CIDP treatment.
The results will be used to support the regulatory filing of IVIG in Europe and the US.
CIDP is a neurological disorder characterised by impaired sensation, areflexia, and slow onset of weakness.
Share this article
